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In common with most developing countries, South 
Africa (SA) has a rapidly expanding population. 
Family planning has a central role in slowing 
population growth. Successful use of birth control 
relies on many factors, including economic, medical 
and social. One of the many difficulties faced in supplying adequate 
birth control is the growing lack of availability of a number of birth 
control options. Some of these options are vital for ensuring optimal 
contraception for all who need and want it, while others are useful 
alternative options for those who experience problems with their 
current method(s).
Ulipristal acetate 30 mg (Ella, EllaOne) has been available on 
prescription in Europe and the USA for about 5 years and is now 
available without prescription in most of the European Union, 
the UK, the USA and Canada. Ulipristal acetate is a selective pro­
gesterone receptor modulator.[1] It is used as an oral emergency 
contraceptive up to 120 hours after unprotected intercourse and 
is reasonably effective because of its powerful effect on delaying 
ovulation.[1] It is more effective than the levonorgestrel (LNG) 1.5 mg 
regimen currently available in SA. Like LNG, ulipristal acetate is also 
less effective in women with an increased body mass index (BMI) 
(>30).[1] The increased BMI effect, however, is not as pronounced 
as for LNG or the combined oestrogen/progestin (Yuzpe) method.[1] 
Ulipristal acetate is estimated to be about 60 ­ 70% effective in women 
exposed to pregnancy during the fertile window. This is because it 
is not effective once ovulation has taken place. Owing to its weaker 
ovulation­delaying mechanism, LNG is only 30 ­ 40% effective in 
those who are exposed during the fertile phase, again because it is 
not effective after ovulation has occurred.[1] Ulipristal acetate 5 mg 
(Fibristal) daily for 3 months is also used to treat fibroids.[2]
Our second missing family planning essential is desogestrel 
75  µg (Cerazette), a progestin­only contraceptive pill (POP). 
While desogestrel is available in SA in combination with ethinyl­
oestradiol as Marvelon and Mercilon, it is not available as 
a POP. Cerazette is unique in that it is the only POP that 
reliably suppresses ovulation. [3] All other POPs, irrespective of the 
progestin, do not achieve this, their main mechanism of action 
being their effect on cervical mucus. Desogestrel is not as useful 
in combination with oestrogen where, in common with other 
third­generation progestins, it increases resistance to activated 
protein C and leads to a higher incidence of thrombosis compared 
with second­generation progestins.[4,5] Desogestrel is the parent 
compound of etonogestrel, which is the progestin used in the 
NuvaRing vaginal ring in combination with oestrogen, where it 
is also associated with an increased tendency to thrombosis. [5] 
Etonogestrel is also the progestin used in the Implanon NXT 
implant. Orally or parenterally, desogestrel and its metabolites alone 
do not cause clotting problems.[5]
The third missing essential is an intrauterine device (IUD) or 
intrauterine system (IUS) the dimensions of which will accommodate 
the nulliparous or smaller uterus to provide a more anatomical fit. [6] 
The CHOICE project in St Louis, USA, has provided evidence of 
the success rate of a family planning programme that focuses on 
the use of long­acting reversible contraception (LARC) to obtain 
better long­term outcomes.[7] While ‘one size fits all’ may apply 
perfectly to the Implanon NXT and other implants when used as 
part of an LARC programme (they are also independent of BMI), 
it most certainly does not apply when the IUD or IUS is the LARC 
method being used. The discontinuation rate of the use of IUDs or 
IUSs in nulliparous or adolescent women is high.[8,9] The reason for 
this is that the IUD or IUS works best and gives fewer problems if it 
is situated wholly within the endometrial cavity.[6] This may not be 
possible if the device is too large for the uterine cavity being fitted. 
The endometrial cavity is functionally an isosceles trapezoid[10] in 
which the mean transverse width in multiparous women is 28 mm, 
while in nulliparous women the mean is 24 mm – or as low as 
17 mm.[8] This latter transverse diameter is clearly too small for 
the transverse arms of the Nova­T, Mirena and Copper­T 380A 
devices that are available in the private and/or public sectors in 
SA. LARC methods, including the IUD and IUS, are approved 
for nulliparous women by the World Health Organization, the 
American College of Obstetricians and Gynecologists and the Royal 
College of Obstetricians and Gynaecologists of Great Britain. In 
order to reliably accommodate nulliparous women, devices such 
as the Jaydess (a smaller Mirena), with smaller transverse arms, or 
the GyneFix­200, which is frameless and has no transverse arms, 
which is attached to the uterine fundus, are needed.[8] Long­term 
continuation rates with the GyneFix IUD in nulliparous women are 
usually far higher than with framed devices.[8] Counselling has been 
advised to help reduce the poor IUD continuation rates in young 
women.[9] It is difficult to see how this can overcome anatomical 
disparities.
It would be desirable to have the combined oral contraceptive pill 
Allesse or a generic equivalent available. Allesse contains 100 µg LNG 
and 20 µg ethinyl­oestradiol. This is a lower dose than that found in 
Nordette or its generic counterpart (150 µg LNG and 30 µg ethinyl­
oestradiol), which is the lowest­dose monophasic LNG­containing 
pill currently available. The combined oral contraceptive pills 
containing third­ (and fourth­) generation progestins (e.g. desogestrel, 
gestodene, cyproterone acetate and drospirinone) are clearly second 
choice behind the second­ and first­generation progestins. LNG and 
the other first­generation progestins, e.g. norethisterone, are now 
first choice. The manufacturers of the third­generation progestins 
have paid out many millions of dollars in compensation to women 
who experienced thrombosis while using these products, which 
now contain specific Food and Drug Administration warnings. Also 
desirable would be the availability of medroxy­progesterone by the 
subcutaneous route (Depo­SubQ Provera 104 in the Uniject system), 
which would be a boon for those women interested in and capable of 
administering their own injectable contraception.
Our wish list would be completed by having Jadelle or Sinoplant 
available. These are implants that contain LNG as the progestin, 
and are an alternative for women who experience problems 
with Implanon, a single­rod subdermal  contraceptive implant 
that is inserted just under the skin of a woman’s upper arm 
and contains  etonogestrel, a third­generation progestin. Jadelle or 
Sinoplant are not as easy to insert or remove as Implanon, however.
We can only hope that some, or even all, of these birth control 
options will soon become available to practitioners in SA.
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